Economic evaluation of mental health care;Gesundheitsökonomie psychischer Krankheiten

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 49, Issue 1, 2006, Pages 46-56

  König, Hans Helmut ^a   Friemel, S ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cost of illness studies; Cost effectiveness analysis; Health economics; Mental health care

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT SYSTEM; ECONOMICS; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HUMAN; MENTAL DISEASE; METHODOLOGY; RESEARCH; REVIEW; STATISTICAL MODEL; STATISTICS;

COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; ECONOMICS, MEDICAL; GERMANY; HEALTH CARE COSTS; HUMANS; MENTAL DISORDERS; MODELS, ECONOMIC; RESEARCH;

EID: 33644891675     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-005-1195-2     Document Type: Review

References (49)

1. Jacobi F, Wittchen HU, Holting C et al. (2004) Prevalence, co-morbidity and correlates of mental disorders in the general population: Results from the German Health Interview and Examination Survey (GHS). Psychol Med 34:597-611
2. Statistisches Bundesamt (2004) Gesundheit: Krankheitskosten 2002. Eigenverlag, Wiesbaden
3. Murray CJL, Lopez AD (1996) Global burden of disease. Harvard University Press, Cambridge, MA
4. World Health Organization (2002) Global burden of disease 2002. http://www.who.int/en/
5. Salize HJ, Rössler W (1996) The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation from a German catchment area. Br J Psychiatry 169:42-48
6. Roick C, Kilian R, Matschinger H et al. (2001) Die deutsche Version des Client Sociodemographic and service Receipt Inventory. Psychiatr Prax 28 [Suppl 2]:84-90
7. World Health Organisation (1992) The ICD-10 classification of mental and behavioral disorders: Clinical descriptions and diagnostic guidelines. World Health Organisation, Geneva
8. Friemel S, Bernert S, Angermeyer MC, Konig HH (2005) Die direkten Kosten von depressiven Erkrankungen in Deutschland. Ergebnisse aus dem European Study of the Epidemiology of Mental Disorders (ESEMeD) Projekt. Psychiatr Prax 32:113-121
9. Saß H, Wittchen HU, Zaudig M (1998) Diagnostisches und statistisches manual psychischer Störungen DSM IV. Übersetzt nach der vierten Auflage des Diagnostic and Statistical Manual of Mental Disorders der American Psychiatric Association. Hogrefe, Göttingen
10. Salize HJ, Stamm K, Schubert M et al. (2004) Behandlungskosten von Patienten mit Depressionsdiagnose in haus- und fachärztlicher Versorgung in Deutschland. Psychiatr Prax 31:147-156
11. Osterheider M, Franken-Hiep K, Horn R (1998) Gesamtkosten der Schizophrenie und monetäre Bewertung einer Rezidivprohylaxe am Beispiel eines Standard-Depot-Neuroleptikums (Flupentixoldecanoat). Psychiatr Prax 25:38-43
12. von der Schulenburg JMG, Uber A, Höffler J et al. (1998) Untersuchungen zu den direkten Kosten und indirekten Kosten der Schizophrenie. Gesundh Ökon Qual Manag 3:81-87
13. Kissling W, Höffler J, Seemann U et al. (1999) Die direkten und indirekten Kosten der Schizophrenie. Fortschr Neurol Psychiatr 67:29-36
14. Kilian R, Roick C, Matschinger H et al. (2001) Die Analyse von Kostenstrukturen im Bereich der Schizophreniebehandlung mit einem standardisierten Instrumentarium. Psychiatr Prax 28 [Suppl 2]:102-108
15. Salize J (2004) Versorgungskosten von Patienten mit Schizophrenie in Deutschland im Langzeitverlauf. In: Vogel H, Wasem J (Hrsg) Gesundheitsökonomie in der Psychotherapie und Psychiatrie: Gesundheitsökonomische Untersuchungen in der psychotherapeutischen und psychiatrischen Versorgung. Schattauer, Stuttgart New York, S 174-182
16. Häfner H, an der Heiden W (1989) Effectiveness and cost of community care for schizophrenic patients. Hosp Community Psychiatry 40:59-63
17. Rice DP, Miller LS (1996) The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N (eds) Handbook of mental health economics and health policy; Schizophrenia. Wiley, Chichester, pp 321-334
18. Hu TW, Hargreaves WA, Shumway M (1996) Estimating costs of schizophrenia and its treatment. In: Moscarelli M, Rupp A, Sartorius N (eds) Handbook of mental health economics and health policy; Schizophrenia. Wiley, Chichester, pp 359-371
19. Kessler RC, Frank RG (1997) The impact of psychiatric disorders on work loss days. Psychol Med 27:861-873
20. Mulvany F, Byrne M, O'Callaghan E (1994) Social class of origin and schizophrenia. Schizophrenia Res 11:97
21. Hannoveraner Konsensus Gruppe (1999) Deutsche Empfehlung zur gesundheitsökonomischen Evaluation - Revidierte Fassung des Hannoveraner Konsens. Gesundh Ökon Qual Manag 4:62-65
22. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
23. Roick C, Kilian R, Angermeyer MC (2004) Zur Aussagefähigkeit gesundheitsökonomischer Analysen in der Psychiatrie: Eine Untersuchung am Beispiel der indirekten Kosten schizophrener Psychosen. In: Vogel H, Wasem J (Hrsg) Gesundheitsökonomie in der Psychotherapie und Psychiatrie: Gesundheitsökonomische Untersuchungen in der psychotherapeutischen und psychiatrischen Versorgung. Schattauer, Stuttgart New York, S 21-31
24. Greenberg PE, Kessler RC, Birnbaum HG et al. (2003) The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475
25. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER (1993) The economic burden of depression in 1990. J Clin Psychiatry 54:405-418
26. Kind P, Sorensen J (1993) The costs of depression. Int Clin Psychopharmacol 7:191-195
27. Stoudemire A, Frank R, Hedemark N et al. (1986) The economic burden of depression. Gen Hosp Psychiatry 8:387-394
28. Thomas CM, Morris S (2003) Cost of depression among adults in England in 2000. Br J Psychiatry 183:514-519
29. Roick C, Kilian R, Angermeyer MC (2001) Die indirekten Kosten schizophrener Psychosen. Eine Untersuchung der Komponenten und Berechnungsmöglichkeiten krankheitsbedingter Ressourcenverluste. Gesundh Ökon Qual Manag 6:36-43
30. Collegium Internationale Psychiatriae Scalarum (CIPS) (1996) Internationale Skalen für Psychiatrie. Beltz-Test GmbH, Go7die;ttingen
31. Priebe S, Oliver JPJ, Kaiser W (1999) Quality of life and mental health care. Wrightson Biomedical, Petersfield
32. Mory C, Matschinger H, Roick C et al. (2001) Die deutsche Version der Verona Service Satisfaction Scale (VSSS-54). Ein Instrument zur Erfassung der Patientenzufriedenheit mit psychiatrischer Behandlung. Psychiatr Prax 28 [Suppl 2]:91-96
33. Gold M, Siegel J, Russel L, Weinstein M (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
34. Brazier J, Deverill M, Green C et al. (1999) A review of the use of health status measures in economic evaluation. Health Technol Assess 3:i-iv, 1-164
35. The EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
36. Dolan P (1999) Whose preferences count? Med Decis Making 19:482-486
37. Chisholm D, Healey A, Knapp M (1997) QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 32:68-75
38. Voruganti LN, Awad AG, Oyewumi LK et al. (2000) Assessing health utilities in schizophrenia. A feasibility study. Pharmacoeconomics 17:273-286
39. Katschnig H (2000) Schizophrenia and quality of life. Acta Psychiatr Scand Suppl 102:33-37
40. König HH (2004) Messung von Patientenpräferenzen in der Psychiatrie. Eine Literaturübersicht über den Einsatz von Standard Gamble, Time Trade-Off und Contingent Valuation bei Depression und Schizophrenie. Psychiatr Prax 31:118-127
41. Sapin C, Fantino B, Nowicki ML, Kind P (2004) Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2:20
42. Prieto L, Sacristan JA, Hormaechea JA et al. (2004) Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 20:827-835
43. Baronet AM (1999) Factors associated with caregiver burden in mental illness: A critical review of the research literature. Clin Psychol Rev 19:819-841
44. Basu A, Meltzer D (2005) Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 24:751-773
45. Olsen JA, Smith RD (2001) Theory versus practice: A review of "willingness-to-pay" in health and health care. Health Econ 10:39-52
46. Barrett B, Byford S, Knapp M (2005) Evidence of cost-effective treatments for depression: A systematic review. J Affect Disord 84:1-13
47. Basu A (2004) Cost-effectiveness analysis of pharmacological treatments in schizophrenia: Critical review of results and methodological issues. Schizophr Res 71:445-462
48. Hamann J, Leucht S, Kissling W (2003) Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 36:18-26
49. Evers SM, Van Wijk AS, Ament AJ (1997) Economic evaluation of mental health care interventions. A review. Health Econ 6:161-177